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Abstract
Background: Metastasis-associated protein 1 (MTA1), a master dual co-regulatory protein is found to be an integral part of
NuRD (Nucleosome Remodeling and Histone Deacetylation) complex, which has indispensable transcriptional regulatory
functions via histone deacetylation and chromatin remodeling. Emerging literature establishes MTA1 to be a valid DNA-
damage responsive protein with a significant role in maintaining the optimum DNA-repair activity in mammalian cells
exposed to genotoxic stress. This DNA-damage responsive function of MTA1 was reported to be a P53-dependent and
independent function. Here, we investigate the influence of P53 on gene regulation function of Mta1 to identify novel gene
targets and functions of Mta1.
Methods: Gene expression analysis was performed on five different mouse embryonic fibroblasts (MEFs) samples (i) the
Mta1 wild type, (ii) Mta1 knock out (iii) Mta1 knock out in which Mta1 was reintroduced (iv) P53 knock out (v) P53 knock out
in which Mta1 was over expressed using Affymetrix Mouse Exon 1.0 ST arrays. Further Hierarchical Clustering, Gene
Ontology analysis with GO terms satisfying corrected p-value,0.1, and the Ingenuity Pathway Analysis were performed.
Finally, RT-qPCR was carried out on selective candidate genes.
Significance/Conclusion: This study represents a complete genome wide screen for possible target genes of a coregulator,
Mta1. The comparative gene profiling of Mta1 wild type, Mta1 knockout and Mta1 re-expression in the Mta1 knockout
conditions define ‘‘bona fide’’ Mta1 target genes. Further extensive analyses of the data highlights the influence of P53 on
Mta1 gene regulation. In the presence of P53 majority of the genes regulated by Mta1 are related to inflammatory and anti-
microbial responses whereas in the absence of P53 the predominant target genes are involved in cancer signaling. Thus, the
presented data emphasizes the known functions of Mta1 and serves as a rich resource which could help us identify novel
Mta1 functions.
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Introduction
Gene expression is central to variety of fundamental cellular
processes that governs the growth and proliferation in mammalian
cell. It is a highly regulated process that is governed by
transcription factors and their co-regulators in the target gene
chromatin [1–3]. Co-regulators are emerging transcription factor
(TF) family that stringently controls the actions of almost ‘‘all’’
nuclear receptors (NRs) through direct binding to NRs rather than
binding to DNA [1–4]. Recent literature highlights the signifi-
cance of coregulators in induction or repression of gene
transcription [5,6]. In fact, the coregulators either function as
enzymes that are essential for gene expression or they regulate
other coregulators through diverse mechanisms [6–10]. There has
been a tremendous focus on understanding the molecular
mechanism of coregulators due to their crucial regulatory role in
almost ‘‘all’’ TF-dependent gene expression and nuclear receptors
dependent functions in several tissues such as breast, ovary,
prostate, gastrointestinal, pancreatic and lungs [5,11,12]. More
interestingly, many cancers over express ‘‘growth coactivators’’
that allow the cancer cell to hijack these molecules which
consequently results in rapid proliferation, malignant process
and rapid metastasis.
One emerging group of chromatin modifiers and coregulators is
the metastasis-associated protein (MTA) family. This family
comprises three different known genes (MTA1, MTA2, and
MTA3) and is an integral part of the NuRD (Nucleosome
Remodeling and Histone Deacetylation) complex that has
indispensable transcriptional regulatory functions via histone
deacetylation and chromatin remodeling [13,14]. MTA1, the
founding member of the MTA family was initially identified
through differential screening of a cDNA library from rat
metastatic breast tumors as an upregulated gene [15,16].
Subsequent studies found MTA1 to be widely up-regulated in
various human cancers and established to be involved in
tumorigenesis, tumor invasion, and metastasis [13,17]. Owing to
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17135its name as a coregualtor the repressor function of MTA1 is
observed through its direct interaction with ERa [18] and HDACs
which represses estrogen-responsive element (ERE) transactivation
activity in a HDAC-sensitive manner that promotes the develop-
ment of hormone-independent growth of breast cancer cells. In
addition, MTA1-NuRD complex was also reported to negatively
regulate BRCA1 transcription by physically associating with an
atypical estrogen-responsive element (ERE) on the BRCA1
promoter [19]. The transcription activator function of MTA1 is
evident from reports showing the stimulation of breast cancer-
amplified sequence 3 (BCAS3) [20] and paired box gene 5 (Pax 5)
[21] promoters mainly through the interaction with RNA
polymerase II. It is noteworthy that the MTA family members
exist in distinct NuRD complexes, and functional redundancy is
lacking among MTA family members [22].
Further, recent studies from this laboratory have discovered for
the first time that MTA1 is a bona-fide DNA-damage responsive
protein due to the induction of intracellular levels of MTA1 by
Figure 1. Schematic showing the experimental design of the study to identify the Mta1 regulated genes with/without the effect of
P53. RNA was extracted from all the samples Wild Type (WT), Mta1 knock out (Mta1-KO), Mta1 Re-expression in the Mta1 knock out MEFS (Mta1-KO/
Mta1), P53 knock out (P53-KO), Mta1 over expression (OE) in the P53 knock out MEFs ( P53-KO/Mta1). cDNA was prepared, processed and hybridized
onto the Affymetrix Mouse Exon 1.0 ST arrays followed by the data analysis. Samples were compared to identify the differentially regulated genes and
in turn the genes regulated by Mta1 in p53 dependent/independent manner and irrespective of P53 status. Candidate genes were selected; these
genes were validated using RT-qPCR assays in MEFs followed by RT-qPCR assays in MCF-7 human breast cancer cell line with the human homologs of
the candidate mouse genes.
doi:10.1371/journal.pone.0017135.g001
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PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e17135Figure 2. Principle Component Analysis as a quality control. All the sample sets (each in triplicates) were plotted in the 3-D PCA-plot. Out of
the 4 total PCA components, components 1, 2 & 4 were plotted on columns X, Y & Z respectively.
doi:10.1371/journal.pone.0017135.g002
Table 1. Top 25 differentially expressed Affymetrix Mouse Exon 1.0 St Array probe sets in MEFs between the wild type and Mta1
knock out.
refseq Gene Symbol FC Reg Gene Description
NM_146015 Efemp1 100.24 up epidermal growth factor-containing fibulin-like extracellular
matrix protein 1
NM_009099 Trim30 79.45 up tripartite motif-containing 30
NM_133871 Ifi44 79.08 up interferon-induced protein 44
NM_009252 Serpina3n 72.25 up serine (or cysteine) peptidase inhibitor, clade A, member 3N
NM_008331 Ifit1 71.62 up interferon-induced protein with tetratricopeptide repeats 1
NM_015784 Postn 49.40 up periostin, osteoblast specific factor
NM_009846 Cd24a 47.95 down CD24a antigen | predicted gene, EG621324
NM_134086 Slc38a1 42.67 down solute carrier family 38, member 1
NM_001033767 EG240327 41.75 up predicted gene, EG240327
NM_001111059 Cd34 40.98 down CD34 antigen
NM_011409 Slfn3 34.62 up schlafen 3
NM_001085522 RP24-320O9.1 32.71 up novel KRAB box containing protein
NM_010681 Lama4 30.71 up laminin, alpha 4
NM_007833 Dcn 30.43 up decorin
NM_009251 Serpina3g 30.43 up serine (or cysteine) peptidase inhibitor, clade A, member 3G
NM_023386 Rtp4 28.17 up receptor transporter protein 4
NM_010917 Nid1 27.87 up nidogen 1 | similar to Nid1 protein
NM_008409 Itm2a 26.76 up integral membrane protein 2A
NM_011854 Oasl2 26.58 up 29-59 oligoadenylate synthetase-like 2
NM_008489 Lbp 26.45 up lipopolysaccharide binding protein
NM_019955 Ripk3 25.19 up receptor-interacting serine-threonine kinase 3
NM_025711 Aspn 23.86 up asporin
NM_025949 Rps6ka6 23.80 down ribosomal protein S6 kinase polypeptide 6
NM_025961 Gatm 23.37 down glycine amidinotransferase (L-arginine:glycine
amidinotransferase)
NM_001001892 EG630499 23.27 up histocompatibility 2, K1, K region
Top 25 probe sets with fold change of 2.0 or more and FDR less than 0.05 are shown. Wild type cells are the control against the knock out cells as treatment.
doi:10.1371/journal.pone.0017135.t001
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damage response and contributes to double-strand DNA break
repair [23]. One of the main DNA damage responsive
mechanisms employed by MTA1 is through direct interaction
and controlling the stability of P53 [24]. P53 is a well-studied
tumor suppressor protein which plays a central role in preserving
the genomic integrity in response to DNA damage, through
inhibiting its ubiquitination by E3 ubiquitin ligases, mouse double
minute 2 (Mdm2) and constitutive photomorphogenic protein 1
(COP1), thereby regulating the P53-dependent DNA repair [25–
27]. Interestingly, these events could be reversed by MTA1
reintroduction, indicating that MTA1 interjects into the P53-
dependent DNA repair [24]. This identified interplay between
oncogene (MTA1) and tumor suppressor (P53) exemplifies the
highly complex check point mediated ‘‘failsafe mechanism’’ that
controls the mitogenic signaling. Moreover, studies from our
laboratory illustrated the participation of MTA1 in a P53-
independent DNA damage response. MTA1-histone deacetylase
2 (HDAC2) complexes recruit P53-independent transcriptional
corepressor, p21WAF1 [28,29] onto two selective regions of the
p21WAF1 promoter which increases p21WAF1 binding to
proliferating cell nuclear antigen (PCNA). This decreases the
nuclear accumulation of PCNA in response to ionizing radiation
[30]. MTA1 is also shown to be stabilized by UV radiation in
ATR (Ataxia teleangiectasia and Rad3-related) kinase dependent
manner and there is a subsequent increase in MTA1 binding to
ATR. However, depletion of MTA1 compromises the ATR-
mediated Chk1 activation following UV treatment. Consequently,
expression of MTA1 in P53-null cells results in increased induction
of histone, cH2AX [31] foci and DNA double strand break repair
and decreased DNA damage sensitivity following ionizing
radiation treatment. These early studies linking the MTA/NuRD
complexes to DNA-damage response were further supported by
more recent reports showing the recruitment of the NuRD
complexes to the site of DNA damage [32,33] Together, the P53-
independent role of MTA1 in DNA damage response connects
NuRD complex and DNA-damage response pathways [34].
To further characterize the potential mechanism for the
functional role of MTA1 in DNA repair, we performed a complete
gene profiling study to identify differences between the MTA1
+/+
and MTA1
2/2 mouse embryonic fibroblasts (MEFs) in the
presence and absence of P53, using Affymetrix Mouse Exon 1.0
ST arrays. The comparative gene profiling of Mta1 wild type,
Mta1 knock out and Mta1 knockout in which Mta1 was
reintroduced conditions define ‘‘bona fide’’ Mta1 target genes
such as Egr2, Phf17, and Aw551984. In depth analyses of the
Table 2. Top 25 differentially expressed Affymetrix Mouse Exon 1.0 St Array probe sets in MEFs between the Mta1 knock out and
Mta1 knock out/Mta1.
refseq Gene Symbol FC Reg Gene Description
NM_134066 Akr1c18 14.98 up aldo-keto reductase family 1, member C18
NM_025711 Aspn 9.58 down asporin
NM_029803 Ifi27 8.86 down interferon, alpha-inducible protein 27
NM_178737 AW551984 6.75 down Mouse homolog of human gene VWA5A
NM_007621 Cbr2 6.01 down carbonyl reductase 2
NM_011595 Timp3 5.67 up tissue inhibitor of metalloproteinase 3
NM_027495 Tmem144 5.13 up transmembrane protein 144
NM_029000 Gvin1 4.89 down GTPase, very large interferon inducible 1
NM_013585 Psmb9 4.53 down proteasome (prosome, macropain) subunit, beta type 9
(large multifunctional peptidase 2)
NM_028608 Glipr1 4.36 down GLI pathogenesis-related 1 (glioma)
NM_023422 Hist1h2bc 3.91 down histone cluster 1
NM_001097644 Ccnyl1 3.91 down cyclin Y-like 1
NM_008630 Mt2 3.78 up metallothionein 2
NM_008604 Mme 3.78 down membrane metallo endopeptidase
NM_008728 Npr3 3.74 up natriuretic peptide receptor 3
NM_009251 Serpina3g 3.73 down serine (or cysteine) peptidase inhibitor, clade A,
member 3G
NM_011979 Vnn3 3.68 down vanin 3
NM_007817 Cyp2f2 3.65 down cytochrome P450, family 2, subfamily f, polypeptide 2
NM_008185 Gstt1 3.64 down glutathione S-transferase, theta 1
NM_054077 Prelp 3.58 down proline arginine-rich end leucine-rich repeat
NM_053078 D0H4S114 3.57 down DNA segment, human D4S114
NM_011579 Tgtp 3.50 down T-cell specific GTPase
NM_012043 Islr 3.45 down immunoglobulin superfamily containing leucine-rich
repeat
NM_009846 Cd24a 3.32 up CD24a antigen
NM_133903 Spon2 3.26 down spondin 2, extracellular matrix protein
Top 25 probe sets with fold change of 2.0 or more and FDR less than 0.05 are shown. Mta1 knock out cells are the controls and Mta1-KO/Mta1 is the treatment.
doi:10.1371/journal.pone.0017135.t002
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along with P53 knockout and P53 knockout with Mta1 over
expression clearly indicates influence of P53 on Mta1 gene
regulation. Mta1 target genes are mostly involved in inflammatory
and anti-microbial responses in the presence of P53 whereas the
predominant target genes and functions identified appear to be
related to cancer signaling in the absence of P53. Thus, we provide
a complete gene profiling of Mta1 which not only emphasizes the
Figure 3. Genes regulated by Mta1 in the presence and absence of P53.A : Venn diagrams showing the number of genes that are identified
to be genuinely regulated by Mta1 in the presence and absence of P53. (i) The genes shown in WT vs. Mta1-KO (1124) are the genes affected by Mta1
knock out and the genes that are present in Mta1-KO vs. Mta1-KO/Mta1 (184) are affected due to re-expression of Mta1 in the knockout MEFs. The
genes that are differentially regulated in both the sets with opposite trends in the regulation are considered as the ‘bona fide’ genes regulated by
Mta1. ii) Similarly, the intersection of P53-KO and P53-KO/Mta1 represents the genes differentially regulated by Mta1 over expression in the P53-KO
MEFs. i.e. the genes regulated by Mta1 in the absence of P53.This scenario of Mta1 over expression and P53 knock out/mutation mimics most of the
cancers iii) The Venn diagram between genes regulated by Mta1 in the presence of P53, 126 and genes regulated by Mta1 in the absence of P53, 266
gives the genes that are regulated by Mta1 only in the presence of P53, irrespective of P53 status and only in the absence of P53 respectively. B: Heat
maps representing hierarchical clustering of the differentially regulation, plotted using the log2 values of the genes with p-value#0.05 (unpaired t-
test) and with fold change of at least 2 between the comparisons Mta1 knock out vs. Mta1 knock out/Mta1 and P53 knock out vs. P53 knock out/Mta1.
Each column represents a sample plotted in triplicates and each row in the heat map represents a gene that is differentially regulated in that
particular comparison of samples. The color scale represents the degree of expression of the gene, green being the lowly expressed (below 23.0) and
red being (above +3.0) the highly expressed genes in the sample sets with black as the center of the scale at ‘0’. C: Pie diagrams showing the
percentage of up-regulated and the down-regulated genes in each sample comparison. The red segment of the pie represents the up-regulated
genes whereas; the green segments represent the down regulated genes.
doi:10.1371/journal.pone.0017135.g003
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functions.
Results
Strategy to identify the possible target genes of MTA1 in
a P53 dependent and independent manner
The aim of the study is to identify the genes that are regulated
by Mta1 in P53 dependent and independent manners. The
detailed schematic of the strategy followed to identify the genes is
shown in Figure 1. Murine Embryonic Fibroblasts (MEFs) from
wild type, Mta1 knockout [35] and P53 knockout mice embryos
[36] were isolated and cultured to obtain five different types of
samples, each in triplicates, for the identification of the genes that
are regulated by Mta1 with/without the P53 background. The
sample sets are as follows: 1) Mta1-Wildtype (WT), 2) Mta1-
knockout (Mta1-KO) [23], 3) Mta1 transfected into the Mta1-knock
out MEFs (Mta1-KO/Mta1), 4) P53-Knock (P53-KO) and 5) Mta1
over expressed in the P53-Knockout MEFs (P53-KO/Mta1) [30].
The protein levels of Mta1 in all the five samples are compared
using Western blot probed with Mta1 antibody (Figure S1). Total
RNA was isolated from the MEFs, cDNA was prepared, processed
and hybridized onto Affymetrix Mouse Exon 1.0 ST arrays. The
gene expression data from all the samples were obtained, quality
control steps were performed and the data was analyzed using
GeneSpring GX 10.0.2 (Agilent Technologies).
Genes regulated by Mta1 under different conditions were
identified by performing gene expression analysis followed by the
Gene Ontology analysis. Ingenuity Pathways Analysis (IPA)
(Ingenuity Systems, Inc) was used to identify top 15 statistically
significant functions of the differentially regulated genes and top
15 canonical pathways in which these genes could play a role.
Candidate genes were selected based upon the functions and our
laboratory interests. RT-qPCR assays were performed to validate
the microarray gene regulation of the selected candidate genes.
The differential regulation of the candidate genes was confirmed
using MEFs and the MCF7 human breast cancer cell line for the
respective human homologs. Using this strategy, we have
identified a set of genes which, we believe, are regulated by
Mta1 in P53 dependent and independent manners, thus, providing
overall gene profiling of Mta1.
Quality Control and Gene Expression Analysis
We generated cDNAs from the total RNA of the corresponding
MEFs and three biological replicates for each sample were
hybridized. The raw data was obtained and normalized log2 ratio
values were used to identify the differential gene expression levels
across different samples. The quality control of all the samples and
the replicates was analyzed by unsupervised Principle Component
Analysis (PCA) method in which each of the samples, in a differ-
ent color, was plotted in three dimensional (3D) space with
components 1, 2 & 4 along X, Y & Z axes respectively. Figure 2
shows the PCA-plot with replicates of each sample clustered close
to each other illustrating the similarity between the sample
replicates. We performed unpaired t-test with a p-value less than
0.05 and Benjamini Hochberg false discovery rate (FDR) was
applied for the multiple corrections to filter the false positives so
that the statistically significant genes could be obtained.
Genes regulated by Mta1 in the presence of P53 in MEFs
The initial comparison between the Mta1 wild type, the Mta1
knock out and Mta1-re-expression in knockout MEFs was
performed. Although differential expression of the genes between
Mta1 wild type and Mta1 knock out was reported by us earlier
[30], our aim of this study is to identify the genes differentially
regulated among Mta1 wild type, Mta1 knock out and Mta1-KO in
which Mta1 WT was reintroduced. Therefore, we have used the
Table 3. Bona fide Mta1 regulated genes in the presence of
P53 identified from the Affymetrix Mouse Exon 1.0 ST Arrays.
Gene Symbol WT vs. Mta1-KO Mta1-KO vs. Mta1-KO/Mta1
Fold Change Regulation Fold Change Regulation
Cd24a 47.95 down 3.32 up
Iigp1* 41.75 up 3.23 down
Serpina3g* 30.43 up 3.73 down
Lbp* 26.45 up 2.51 down
Aspn* 23.86 up 9.58 down
Ifit3 22.29 up 2.25 down
Apod 20.15 up 2.89 down
Irgb10 18.67 up 2.2 down
Ccnyl1 18.12 up 3.91 down
Apol9a 17.31 up 2.37 down
Apol9b* 17.31 up 2.37 down
Oas1a 15.93 up 2.19 down
Zbp1 13.03 up 3.15 down
Smpdl3b 12.92 down 2.26 up
Islr* 12.85 up 3.45 down
Steap4* 12.37 up 2.55 down
Pcdhb9 12.31 up 2.22 down
Timp3 12.03 down 5.67 up
Ifi27 11.75 up 8.86 down
Irf7 11.17 up 2.04 down
Prelp* 11.12 up 3.58 down
Psmb9 11.05 up 4.53 down
AW551984 11.04 up 6.75 down
Pcdhb8 9.98 up 2.82 down
Tspan13 9.95 up 2.03 down
Il1rn 9.87 up 2.34 down
Gvin1 9.87 up 4.89 down
Lpl 9.54 up 2.36 down
Il1rl1* 9.08 up 2.32 up
Oas2 8.78 up 2.98 down
Trim12 8.32 up 2.04 down
Adam23 8.32 up 2.74 down
Ednra 8.06 up 2 down
A4galt* 7.21 up 2.85 down
Tap1 7 up 2.89 down
Ened 6.88 up 2.31 up
Vnn3 6.81 up 3.68 down
Dhx58 6.49 up 2.26 down
Mgp 6.29 up 2.64 down
Ces1 6.14 up 2.9 down
Slc16a4 5.97 up 3 down
*Genes (32) regulated by Mta1 irrespective of P53 status. Figure 3A (lower
panel).
Note: Continued in Table S5.
doi:10.1371/journal.pone.0017135.t003
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knockout conditions were compared, 1124 genes were reported
with a fold change $62.0 and with the p-value,0.05. These 1124
genes were either directly or indirectly regulated by Mta1. Top 25
differentially expressed Affymetrix probes are shown in Table 1
(complete list is shown in Table S1, statistically summary is shown
in Table S2). It is noteworthy that a gene encoding epidermal
growth factor-containing fibulin-like extra cellular matrix protein 1
(EFEMP1) is identified to be up-regulated by 100 fold with the
highest fold change regulation in the Mta1 knockout MEFs when
compared with the wild type Mta1 MEFs. Interestingly, Sadr-
Nabavi et al., (2009) reported a reduction in RNA and protein
levels of EFEMP1 in human sporadic breast cancer tissues [37]
which imply that over expression of Mta1 could lead to down
regulation of EFEMP. In addition, we also found that the gene
encoding CD24/HSA had the maximum fold change among the
down regulated genes. CD24 is a cell adhesion molecule that is
expressed on the surface of the infected cells [38].
When Mta1 was transfected into the Mta1 knock-out MEFs and
compared against the Mta1-KO, 184 differentially regulated genes
were identified. The top 25 differentially regulated genes based upon
fold change are shown inTable 2 (the entirelist isshown inTable S3
and statistical summary in Table S4). Out of these 184 genes, 126
genes were found to be present in WT Vs Mta1-KO as well (1124
genes, Figure 3A top panel). Majority of these 126 genes appear to
restore their functioning when Mta1is transfected backintothe Mta1
knock out cells. Among these 126 genes except 6 genes, rest of them
regained their expression levels similar to WT. Therefore these
represent ‘‘bona fide’’ Mta1 target genes (Table 3 and Table S5).
Since P53 is present in all the three samples they reflect the number
of genes influenced by MTA1 in the presence of P53.
Genes regulated by Mta1 in a P53-independent manner
Here we identified the genes that are regulated by Mta1 in a
P53-independent manner. Differential gene expression analysis
was performed by comparing the P53 knock out cells and P53
knock out/Mta1 over expressed cells [30]. All the genes with p-
value,0.05 and fold change expression $62.0 were considered as
statistically significant. The statistical analysis of the data generated
a set of 266 genes, top 25 differentially regulated genes are shown
Table 4. Top 25 differentially expressed Affymetrix Mouse Exon 1.0 St Array probe sets between the P53 knock out MEFs and the
P53 knock out MEFs in which Mta1 is over expressed.
refseq Gene Symbol FC Reg Gene Description
NM_008489 Lbp 26.89 down lipopolysaccharide binding protein
NM_015784 Postn 14.70 down periostin, osteoblast specific factor
NM_008607 Mmp13 13.37 down matrix metallopeptidase 13
NM_008760 Ogn 12.46 down osteoglycin
NM_011339 Cxcl15 12.39 down chemokine (C-X-C motif) ligand 15
NM_008491 Lcn2 9.68 down lipocalin 2
NM_001014423 Abi3bp 9.31 down ABI gene family, member 3 (NESH) binding
protein
NM_199468 Zcchc5 7.85 down zinc finger, CCHC domain containing 5
NM_011704 Vnn1 7.22 down vanin 1
NM_009373 Tgm2 7.22 down transglutaminase 2, C polypeptide
NM_054098 Steap4 7.06 down STEAP family member 4
NM_011315 Saa3 6.70 down serum amyloid A 3
NM_010582 Itih2 6.51 down inter-alpha trypsin inhibitor, heavy chain 2
NM_009144 Sfrp2 6.46 down secreted frizzled-related protein 2
NM_010809 Mmp3 6.39 down matrix metallopeptidase 3
NM_008728 Npr3 5.80 down natriuretic peptide receptor 3
NM_172463 Sned1 5.70 down sushi, nidogen and EGF-like domains 1
NM_022814 Svep1 5.62 down sushi, von Willebrand factor type A, EGF and
pentraxin domain containing 1
NM_007621 Cbr2 5.55 down carbonyl reductase 2
NM_009251 Serpina3g 5.53 down serine (or cysteine) peptidase inhibitor, clade A,
member 3G
NM_025711 Aspn 5.47 down asporin
NM_144938 C1s 5.23 down complement component 1, s subcomponent
NM_031167 Il1rn 5.15 down interleukin 1 receptor antagonist
NR_001592 H19 5.14 down
NM_030601 Clca2|Clca1 4.83 down chloride channel calcium activated 2 | chloride
channel calcium activated 1
Top 25 probe sets with fold change of 2.0 or more and FDR less than 0.05 are shown. P53-KO is considered as the control and P53-KO/Mta1 is considered as the
treatment.
doi:10.1371/journal.pone.0017135.t004
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in Table S7) and the Venn diagram in Figure 3A middle panel
shows the number of genes differentially regulated. When Bona
fide Mta1 regulated genes (126) were compared with p53
independent regulated genes of Mta1, 32 genes were shown to
be regulated by Mta1 irrespective of p53 status (Figure 3A lower
panel, these genes are marked with asterisks in Table 3 and Table
S5). Since, both the samples are P53-knockout MEFs, with one of
them carrying over expression of Mta1; the differentially expressed
genes were regulated by Mta1 independent of P53.
Hierarchical clustering analysis reveals influence of P53
on MTA1 gene regulation
Further, we performed the hierarchical clustering analysis with
the genes that were differentially regulated between the Mta1-KO
vs. Mta1-KO/Mta1, and P53-KO vs. P53-KO/Mta1. The
normalized log2 ratio values of the differentially regulated genes
in each comparison were used to obtain the heat maps (Figure 3B).
The gene leaf nodes were optimized in the heat maps representing
the differential regulation of the genes between the samples. Color
scale of the heat map depicts red as the highly expressed, green as
low expressed and black as intermittent level of gene expression.
Figure 3B shows the heat maps of all the comparisons, Mta1-KO
with Mta1-KO/Mta1 and P53-KO with P53-KO/Mta1 represent-
ing the differential expression of the genes. We found that 64% of
the differentially regulated genes were up-regulated in WT vs.
Mta1-KO where as it greatly reduced to 30% in Mta1-KO vs.
Mta1-KO/Mta1 followed by further reduction to 22% in P53-KO
vs. P53-KO/Mta1. In the case of differentially regulated genes that
were down regulated, the percentage of down regulated genes was
36% in WT vs. Mta1-KO, 70% in Mta1-KO vs. Mta1-KO/
Mta1and 78% in P53-KO vs. P53-KO/Mta1. In summary, we
observe 78% of genes down regulated by Mta1 due to the absence
of P53 whereas about 64% of Mta1 regulated genes were up
regulated in the presence of P53 (Figure 3C).
Figure 4. Gene Ontology (GO) analysis of was performed using
Gene Spring GX 10.0.2 (Agilent technologies Inc and Strand
Life Sciences Pvt Ltd). With the gene set comparisons that were
described in the figure 3A GO analysis was performed. Pie chart A
shows the statistically significant (P,0.1) differentially regulated genes
between wild type and Mta1-KO samples matching with three broad
GO terms (Cellular components, Biological process and Molecular
Function), Pie chart B (Mta1-KO and Mta1-KO/Mta1) shows the GO
terms matching with the differentially regulated genes in this
comparison. Pie chart C and pie chart D show the same for bona fide
Mta1 regulated genes in the presence of P53 (126) and P53-KO vs. P53-
KO/Mta1 (genes regulated by Mta1 in the absence of P53,266)
respectively.
doi:10.1371/journal.pone.0017135.g004
Table 5. GO Analysis of the genes differentially regulated between the WT & Mta1-KO with $2.0 fold change.
GO ACCESSION GO Term p-value
Corrected
p-value
Count in
Selection
% Count in
Selection
Count in
Total
% Count in
Total
GO:0005576 extracellular region 1.87E-27 4.82E-22 286 44.83 2627 14.72
GO:0044421 extracellular region part 2.27E-25 2.92E-20 244 38.24 2157 12.08
GO:0005615 extracellular space 2.75E-23 2.36E-18 229 35.89 2038 11.42
GO:0007155 cell adhesion 2.10E-17 1.08E-12 78 12.23 541 3.03
GO:0022610 biological adhesion 2.10E-17 1.08E-12 78 12.23 541 3.03
GO:0006955 immune response 1.17E-14 5.02E-10 59 9.25 405 2.27
GO:0031012 extracellular matrix 9.71E-14 3.57E-09 50 7.84 279 1.56
GO:0005578 proteinaceous
extracellular matrix
2.06E-13 6.64E-09 49 7.68 275 1.54
GO:0005488 binding 2.37E-13 6.80E-09 446 69.91 10687 59.87
GO:0005515 protein binding 7.79E-12 2.01E-07 325 50.94 5094 28.54
GO:0002376 immune system process 8.35E-11 1.96E-06 59 9.25 658 3.69
GO:0009653 anatomical structure
morphogenesis
4.52E-09 9.71E-05 28 4.39 1002 5.61
GO:0005509 calcium ion binding 5.37E-09 9.89E-05 88 13.79 791 4.43
GO:0032502 developmental process 5.06E-09 9.89E-05 84 13.17 2682 15.03
GO:0048513 organ development 7.10E-09 1.14E-04 28 4.39 1339 7.50
Note: Continued in Table S8.
doi:10.1371/journal.pone.0017135.t005
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cellular functions regulated by Mta1 in the presence/
absence of P53
To further investigate the functions of the genes regulated by
Mta1, we performed Gene Ontology (GO) analysis on all the sets
of genes that are regulated by Mta1 with/without P53 background
with a p-value cutoff set to 0.1. The possible functions of the gene
sets were broadly classified, in GO program, into three categories
namely i) Cellular Component ii) Molecular Function and iii)
Biological Process. We found that the 40.23% of the differentially
regulated genes in the comparison of WT vs. Mta1-KO, with p-
value: 0.1617 related to molecular function, followed by 34.97%
with p-value 0.148 connected to Cellular Component and 24.79%
of the genes with p-value 0.0944 were associated with the
biological process (Figure 4A). In contrast to the above, when
Mta1-KO and Mta1-KO with reintroduced Mta1 were compared
there were no genes that match the GO terms in the Molecular
functioning, whereas majority of them (77.78%, p-value: 0.6994)
were related to the cellular component (Figure 4B). With the
corrected p-value cut off 0.1 and in the presence of P53, Mta1
doesn’t regulate any genes responsible for molecular functioning.
The majority of the genes (78.12%) are associated with Cellular
Component and 21.88% are associated to Biological Process
(Figure 4C). In contrast to the above, in. the absence of P53,
49.8% (p-value: 0.1212) differentially expressed genes were linked
to the Cellular Component, 30.61% (p-value: 0.1777) to Molecular
Function and 19.59% (p-value: 0.1253) related to Biological
Process (Figure 4D). Tables with GO terms for all the above
mentioned comparisons are shown in Table 5, 6, 7 and 8
respectively. Table 5 and Table 8 are continued as Tables S8 and
S9 respectively.
Ingenuity Pathways Analysis highlights the critical role of
Mta1 in cancer signaling in the presence/absence of P53
Ingenuity pathways analysis was performed on all the genes
that were identified to be regulated by Mta1 with/without P53.
With p-value,0.05, Fischer’s exact test was applied and we found
top 15 significant functions and canonical pathways in which the
genes regulated by Mta1 might play a significant role. The most
likely functions of the genes regulated by Mta1 in the presence of
P53 are Inflammatory Response followed by Cancer and
Gastrointestinal Diseases (Figure 5 upper panel). Top 15
canonical pathways of these genes were identified with the p-
value,0.05 and threshold value of log (p-value): 0.05. The
significant pathways which include LXR/RXR activation,
Interferon signaling, Antigen presentation pathway and Activa-
tion of IRF by cytosolic pattern Recognition Receptors were
shown in Figure 5 (lower panel). From these observations we
propose that Mta1 might have critical functional role in orphan
nuclear receptor activation, inflammation and infections. Simi-
larly, top 15 plausible functions of the genes regulated by Mta1 in
the absence of P53 were identified and shown in Figure 6 (upper
panel). The most significant function of the genes was found to be
related to ‘Cancer’ followed by ‘Cellular Movement’ and
‘Connective Tissue Disorders’. The top 15 canonical pathways
in which the genes might be involved were identified and shown
in the Figure 6 (lower panel). The most significant canonical
pathway identified is ‘Acute Phase response Signaling’ followed
by Colorectal Cancer Metastasis Signaling, Hepatic fibrosis and
‘Bladder Cancer Signaling’. Clearly the genes regulated by Mta1
in the absence of P53 highlight the typical oncogenic character of
Mta1 and its possible major role in several cancers and oncogenic
signaling pathways.
Table 6. GO Analysis of the genes differentially regulated between the Mta1-KO and Mta1- KO/Mta1 probes with $2.0 fold
change.
GO ACCESSION GO Term p-value
corrected
p-value
Count in
Selection
% Count in
Selection
Count in
Total
% Count
in Total
GO:0044421 extracellular region
part
2.56E-12 0.00 53 72.60 2157.00 12.08
GO:0005615 extracellular space 1.18E-11 0.00 53 72.60 2038.00 11.42
GO:0005576 extracellular region 2.18E-11 0.00 61 83.56 2627.00 14.72
GO:0006955 immune response 1.01E-07 0.01 16 21.92 405.00 2.27
GO:0022610 biological adhesion 6.43E-06 0.28 15 20.55 541.00 3.03
GO:0007155 cell adhesion 6.43E-06 0.28 15 20.55 541.00 3.03
doi:10.1371/journal.pone.0017135.t006
Table 7. GO Analysis of the bona fide Mta1 regulated genes in the presence of P53 with $2.0 fold change.
GO ACCESSION GO Term p-value
corrected
p-value
Count in
Selection
% Count in
Selection
Count in
Total
% Count
in Total
GO:0044421 extracellular region
part
2.30E-12 2.97E-07 43 78.18 2157 12.08
GO:0005615 extracellular space 1.48E-12 2.97E-07 43 78.18 2038 11.42
GO:0005576 extracellular region 8.02E-12 6.89E-07 48 87.27 2627 14.72
GO:0006955 immune response 8.12E-08 0.0052 13 23.64 405 2.27
doi:10.1371/journal.pone.0017135.t007
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human homologs follow similar expression profile in
MEFs and human breast cancer cell lines
Based upon our analysis and our laboratory interest, some of the
genes that were regulated by Mta1 with/without P53 back ground
were selected for the validation using the RT-qPCR assays.
Validations were first performed in the MEFs followed by the
MCF7 human breast cancer cell line. The results showing relative
mRNA levels, for the selected genes, are presented in Figure 7.
The controls are compared with the treatments and if the trend of
expression (up or down regulation) in qPCR is in agreement with
the microarray gene expression, then the respective homologous
genes were selected for further validation in the human breast
cancer cell line (MCF7). Aw551984 gene is the homolog of the
human gene VWA5A, also known as BCSC-1. Monaco et al (1997)
characterized and proposed that this gene could be a tumor
suppressor [39,40]. We found that both Aw551984/VWA5A were
negatively regulated by Mta1 in MEFs and human breast cancer
cells. In the case of VWA5A, the expression trend is similar in
MEFs and MCF7 cells but the difference in expression levels
between the WT and MTA1 knockdown in the MCF7 cell line is
marginal. Up regulation of this gene was observed in Mta1-KO
and MTA1-siRNA knock down samples when compared to the wild
type MEFs and MCF7cells respectively. Another candidate, early
growth response protein 2 [encoded by Egr2] and its human
homolog was found to follow similar trend in MEFs and MCF7
cell line with significant difference in expression levels when
compared between wild type and Mta1-KO. Finally, Phf17,a
known apoptosis promoter which may act as a renal tumor
suppressor [41] is found to be down regulated in the Mta1 knock
out MEFs. As expected the expression pattern of all these
candidates is in agreement with the above described microarray
data. Together, the expression of these representative genes
highlights the possible interplay between the tumor suppressors
(Aw551984, Egr2), apoptotic protein (Phf17) and oncogene (Mta1).
The bar charts (7A, 7B, 7C) in Figure 7 show the expression levels
of these three genes from the RT-qPCR assay and the Affymetrix
microarray data.
We also selected candidate genes that are regulated by Mta1,i n
the absence of P53, from the microarray data and subjected them
to the RT-qPCR validation. The relative expression levels of these
genes in the controls and treatments are shown in the Figure 7
(7D, 7E, 7F). The data clearly shows the agreement between the
microarray and the RT-qPCR results. We have chosen Rnf144a
which contains RING figure motif and established to have role in
protein-DNA and protein-protein interactions. We found that
Rnf144a was upregulated in the absence of P53 and over
expression of Mta1. Another selected candidate was Hmmr, which
encodes Hyaluronan mediated motility receptor protein that is
found to be expressed in the breast tissue. It is notable that the
Hmmr gene was found to be down regulated in P53-KO, whereas it
was up regulated in P53-KO/MTA1 when compared with the
WT. The third candidate gene, Klf15 which encodes a protein
called kruppel like factor-15 was found to be highly up-regulated
in P53-KO MEFs where as it is only weakly up-regulated in P53-
KO/Mta1, when compared with the wild type. The expression
levels from the RT-qPCR assay and the Affymetrix microarray
data are in perfect agreement for all the chosen candidates in
MEFs (Figure 7).
RT-qPCR assays were also conducted with human homologs to
validate the genes that were believed to be regulated by Mta1 in
MEFs. Thisstep of validationisperformed withtheMta1 knock down
(Mta1siRNA) in MCF7compared with the non-target control siRNA.
Similar differential gene expression levels were observed among all
the genes (VWA5A, EGR2, RNF144A, KLF15, and HMMR) which are
similar to the microarray expression profile (Figure 8).
Table 8. GO Analysis of the bona fide Mta1 regulated genes in the absence of P53 with $2.0 fold change.
GO ACCESSION GO Term p-value corrected p-value
Count in
Selection
%Count in
Selection Count in Total % Count in Total
GO:0005576 extracellular region 8.45E-38 2.18E-32 122 89.05 2627 14.72
GO:0044421 extracellular region part 7.08E-29 9.12E-24 99 72.26 2157 12.08
GO:0005615 extracellular space 2.37E-23 2.03E-18 88 64.23 2038 11.42
GO:0005578 proteinaceous extracellular
matrix
1.84E-15 1.19E-10 27 19.71 275 1.54
GO:0031012 extracellular matrix 2.64E-15 1.36E-10 27 19.71 279 1.56
GO:0006954 inflammatory response 3.07E-08 0.00131978 7 5.11 204 1.14
GO:0007155 cell adhesion 1.83E-07 0.00522946 21 15.33 541 3.03
GO:0022610 biological adhesion 1.83E-07 0.00522946 21 15.33 541 3.03
GO:0005509 calcium ion binding 7.26E-07 0.0170145 30 21.90 791 4.43
GO:0009605 response to external stimulus 6.98E-07 0.0170145 7 5.11 465 2.61
GO:0044268 multicellular organismal
protein metabolic process
1.99E-06 0.0264874 5 3.65 16 0.09
GO:0004714 transmembrane receptor
protein tyrosine kinase activity
2.05E-06 0.0264874 7 5.11 61 0.34
GO:0030574 collagen catabolic process 1.99E-06 0.0264874 5 3.65 16 0.09
GO:0008237 metallopeptidase activity 1.68E-06 0.0264874 12 8.76 181 1.01
GO:0044259 multicellular organismal
macromolecule metabolic
process
1.99E-06 0.0264874 5 3.65 16 0.09
Note: Continued in Table S9.
doi:10.1371/journal.pone.0017135.t008
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This study represents a complete genome wide screen for
possible target genes of a transcriptional co regulator, Mta1.I n
addition to identifying ‘‘bona fide’’ Mta1 target genes, the
influence of p53 on Mta1 gene regulation and molecular
function has also been analyzed extensively. Emerging literature
on Mta1 clearly establishes bidirectional interplay between the
oncogene, MTA1 and the tumor suppressor, P53. Although
Mta1 was found to be a component of the Nucleosome
Remodeling and Deacetylase (NuRD) complex, recent studies
from our laboratory establishes the functions of MTA1 in DNA-
damage response in a P53-dependent and -independent manner
[24,30,34]. This raises the compelling question of how P53
i n f l u e n c e st h eg e n er e g u l a t i o n and overall function of MTA1.
We attempted to address this question using microarray
approach. The first goal of identifying ‘‘bona fide’’ Mta1 targets
have been achieved by initial comparison of genes regulated by
Mta1 wild type and the Mta1 knockout. Subsequently, this set of
genes was compared with the set identified from the compar-
ative study of Mta1 knock out vs. Mta1 re-expressed in the knock
out MEFs. The common genes identified from both com-
parisons reflect the Mta1 ‘‘bona fide’’ targets (Table 3 and
Table S5). To achieve the goal of defining oncogenic gene
Figure 5. Ingenuity Pathway Analysis (Ingenuity Systems, Inc) of the genes that were regulated by Mta1 in the presence of P53 was
performed. The significance of each function or canonical pathway is determined based upon the p-values determined using Right tailed Fisher’s
exact test and with threshold less than 0.05. The top 15 possible functions and canonical pathways of the genes regulated by Mta1 in P53 dependent
manner are shown. Ratio of number of genes in a given pathway satisfying the cutoff and total number of genes present in that pathway was
determined by IPA.
doi:10.1371/journal.pone.0017135.g005
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loss of P53 and the over expression of oncogenes such as Mta1
and compared P53 knock out and P53 knockout in which there
was over expression of Mta1 gene. Interestingly, the identified
266 genes (Table 4) are mostly involved in DNA damage
response. This is in agreement with the recently established
Mta1 function in DNA damage which is independent of P53.
Together, these data further illustrate the possible genes that are
regulated by Mta1 ‘‘fail safe’’ mechanism which occurs due to
loss of P53.
The gene ontology analysis again highlights the influence of P53
on Mta1 function. If P53 is present, the targets regulated by Mta1
play no remarkable role in the molecular functions such as
catalytic activity or binding where as in the absence of P53 about
39% of genes regulated by Mta1 are involved in molecular
functions, clearly indicating the influence of P53 on Mta1 gene
regulation. Further extensive comparative analysis of all the data
using IPA and networks reveals two distinct functional themes. In
the presence of P53, the genes regulated by Mta1 are mainly
involved in the inflammatory response cancer and cellular
movement. Whereas, in the absence of P53 the genes regulated
are predominantly related to cancer signaling reflecting the
significance of Mta1 in cancer. In agreement to the above
mentioned observations, the top networks and pathways regulated
by Mta1 in the presence of P53 appear to be antimicrobial
response, inflammatory response and carbohydrate metabolism
(Figure 9). For instance, most of the genes regulated by Mta1
revolve around major complexes such as IRF7 (Interferon
regulatory factor-7), which has been shown to play important role
in the transcriptional activation of virus inducible cellular genes. In
Figure 6. Ingenuity Pathway Analysis (Ingenuity Systems, Inc) of the genes that were regulated by Mta1 in the absence of P53 was
performed. Fisher’s exact test was used and threshold of 0.05 was set as the cutoff. Top 15 functions associated with the genes and the top 15
canonical pathways in which these genes might have a role are shown.
doi:10.1371/journal.pone.0017135.g006
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systemic IFN takes place through IRF7 [42]. Another gene,
Immunity-related GTPases (IRG) that play an important role in
defense against intracellular pathogens and NFKB complex which
has been well ascertained to be regulated by Mta1 were also found
in the network. In agreement with our data recent studies suggest
MTA1 regulating its target genes either by acting as a corepressor
[18,19] or as transcriptional coactivator [20,21] via interacting
with RNA polymerase II. Together, these findings raise the
possibility that Mta1 may play a significant role in protecting
regulation of innate immune response by directly modulating
several pathways including NF-kB signaling [43]. Our data further
supports this notion and emphasizes the role of Mta1 in
inflammation.
In contrast to that, in the absence of P53, Mta1 target genes
appear to be mainly involved in cancer and genetic disorders
Figure 7. RT-qPCR validation of the microarray data showing the differential regulation of the selected genes in the MEFs. The RNA
extracted from the fibroblasts of the wild type (light blue bars) mice was used as the control and the treatments were Mta1-KO (red bars) & Mta1-KO/
Mta1(green bars). In the presence of P53 relative mRNA levels of the genes Aw551984, Egr2, Phf17 were compared in all the three samples. The relative
mRNA levels from microarray for the same sample sets were plotted and compared with the RT-qPCR. As expected, opposite trends of expression
were observed between the knock out and re-expression models. To validate the genes regulated by Mta1 in the absence of P53 relative mRNA levels
were compared among the three samples wild type (light blue bars), P53-KO (dark blue bars) & P53-KO/Mta1(yellow bars) for the genes Hmmr, Klf15,
Rnf144a.The relative mRNA levels from the microarray were plotted and compared with RT-qPCR. Opposite trends of expression were observed
between the P53-KO and P53-KO/Mta1 treatments when compared with the wild type sample.
doi:10.1371/journal.pone.0017135.g007
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were found with well studied cancer molecules such as Kirsten rat
sarcoma viral oncogene homolog (KRAS) [44,45], epidermal
growth factor receptor (EGFR) [46–48] and vascular endothelial
growth factor (VEGF) [49,50] further highlighting the P53-
independent central functions of Mta1 in metastasis and cancer.
Thus, MTA1 appears to be playing distinct molecular functions
depending on the status of P53. In summary, our data presents
complete gene profiling of Mta1 in the presence and absence of
P53 representing a new resource and guide for future area of
Mta1 research which is unexplored but comprises several key
elements that could be employed in the development of
anticancer therapeutics and identification of novel functions of
Mta1.
Materials and Methods
Cell Culture
Wild type Murine Embryonic Fibroblasts (MEFs) and Mta1-
KO MEFs were obtained as described previously [35]. P53 knock
out MEFs were kindly provided by Dr. G. Lozano (M.D.
Anderson Cancer Center, Houston, TX). MEFs and MCF7
(Michigan Cancer Foundation-7 human breast cancer cell line)
were cultured in DMEM/F-12 medium containing 10% fetal
bovine serum (FBS-Difco Laboratories, Detroit, Michigan) and
1% antibiotic-antimycotic solution in a humidified 5% CO2 at
37uC. Cell culture reagents were purchased from Invitrogen
(Carlsbad, CA). Mta1
+/+, Mta1
2/2, Mta1
2/2/Mta1, p53
2/2 and
p53
2/2/Mta1 MEFs have been described previously [23,24].
Human MTA1 and non target control siRNA smart pools were
obtained from Dharmacon, Inc. MCF7 cells were obtained from
ATCC (ATCC number: HTB-22) Transfection into MCF7 cells
was performed with Oligofectamine reagent (Invitrogen) and
manufacturer’s instructions were followed. Cells were collected
after 36–48 hours after transfection.
RNA Extraction & Microarray Gene Expression Arrays
Microarray gene expression assays have been performed as
described previously [30]. In summary total RNA was extracted
from the cells using Trizol (Invitrogen, Carlsbad, CA) and the
Figure 8. RT-qPCR was performed using the RNA obtained from the wild type MCF-7 cells and MCF-7 cells transfected with the
MTA1-siRNA. The differential regulation of the selected genes (EGR2, HMMR, KLF15, RNF144A, and VWA5A) was observed in agreement with the
Microarray and the RT-QPCR in the MEFs.
doi:10.1371/journal.pone.0017135.g008
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concentrations of the extracted RNA were checked using the
Nano-Drop (Thermo scientific). RNA was then purified using
RNeasy Mini Kit (Qiagen, Valencia, CA) and the integrity was
tested on 6000 NanoChips using Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA). Finally, Affymetrix
Mouse Exon 1.0 ST arrays were used for the hybridization, arrays
were scanned and the expression data was obtained in the form of
.CEL files.
Microarray data analysis
To analyze the data generated from the microarray
experiments we used GeneSpring GX 10.0.2 (Agilent technol-
ogies, Inc) software package for the data Quality Control and
the statistical analysis of the microarray data. The method of
Benjamini and Hochberg was applied for the multiple
corrections with a p-value cut-off of 0.05 and fold change
$62.0 to obtain the statistically significant genes. Heat maps
for individual arrays were generated and the hierarchical cluster
analysis was performed using MeV 4.5 [51]. Gene Ontology
analysis was performed using GeneSpring GX 10.0.2 (Agilent
Technologies). All data is MIAME compliant and the raw data
has been deposited in Gene Expression Omnibus (GEO) as
detailed on the Microarray Gene expression Data Society
(MGED) society website (http://www.mged.org/Workgroups/
MIAME/miame.html).
Functional and Network Analysis
We used the Ingenuity pathway Analysis (Ingenuity Systems,
Inc) to find the statistically significant pathways, functions and the
networks in which the identified genes regulated by Mta1are
possibly involved. Fischer’s exact test was used to identify the
significant functions and pathways represented within the
respective gene sets.
RT-qPCR
RT-qPCR analysis was performed following the protocol
described previously [23,24]. In order to validate the microarray
data we selected candidate genes and RT-qPCR assays were
conducted (all the primers used in this study are listed in
Table S10). 2 mg of the total RNA was used for the first strand
cDNA synthesis using the superscript III First-strand sys kit
(Invitrogen), according to the manufacturer’s instructions in 21-ml
reactions. These reactions were diluted 1:10 with nuclease-free
water. Duplicates of the qPCR contained 2-ml of the first strand
cDNA, 1-ml of the intron-spanning primers specific for that
particular mRNA sample, 2 ml of nuclease free water and 5 mlo f
SYBR Green (Bio-Rad, Hercules, CA). Reactions (10 ml) were run
in 96-well optical plates (Bio-Rad, Hercules, CA). Average
threshold cycle (Ct) values of 18S mRNA (chosen as normalizer)
were subtracted from the corresponding average Ct values of a
target mRNA to obtain DCt values. The relative RNA levels were
then expressed as 2
2Dct.
Figure 9. Gene network analysis shows that the genes regulated by Mta1 in the presence of P53 are involved in the networks
associated with antimicrobial and inflammatory responses (statistically most significant network). When compared with the wild type
MEFs, the genes that were up regulated in Mta1 knockout MEFs are shown in red and the down regulated genes are shown in green. The network
with the highest score from the IPA analysis was considered to be the most significant network and majority of the genes that were found in this
network were up-regulated.
doi:10.1371/journal.pone.0017135.g009
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Figure S1 Western blot assay of the five samples (WT, Mta1-
KO, Mta1-KO/Mta1, P53-KO, and P53-KO/Mta1) was per-
formed using Mta1 antibody as described previously [30] and the
levels of Mta1 in all the five conditions are shown. a-Tubulin was
used as the internal control.
(TIF)
Table S1 Complete list of the differentially expressed probe sets
on the Affymetrix Mouse Exon 1.0 ST arrays between the wild
type and the Mta1 knock out MEFs.
(XLS)
Table S2 The statistical summary of the log 2 ratio values for the
differentially expressed probe sets on the Affymetrix Mouse Exon
1.0 ST arrays between the wild type and the Mta1 knock out
MEFs.
(DOC)
Table S3 Complete list of the differentially expressed probe sets
on the Affymetrix Mouse Exon 1.0 ST arrays between the Mta1
knockout (Mta1-KO) MEFs and Mta1 reintroduced into the knock
out MEFs (Mta1-KO/Mta1).
(XLS)
Table S4 The statistical summary of the log 2 ratio values for the
differentially expressed probe sets on the Affymetrix Mouse Exon
1.0 ST arrays between the Mta1 knockout (Mta1-KO) MEFs and
Mta1 reintroduced into the knock out MEFs (Mta1-KO/Mta1).
(DOC)
Table S5 The ‘Bona fide’ genes that are regulated by Mta1.
(DOC)
Table S6 Complete list of the differentially expressed probe sets
on the Affymetrix Mouse Exon 1.0 ST arrays between the P53
knock out (P53-KO) and P53 knockout MEFs with over expression
of Mta1(P53-KO/Mta1).
(XLS)
Table S7 The statistical summary of the log 2 ratio values for the
differentially expressed probe sets on the Affymetrix Mouse Exon
1.0 ST arrays in MEFs between the P53 knockout (P53-KO) and
P53 knockout MEFs with over expression of Mta1 (P53-KO/
Mta1).
(DOC)
Table S8 Gene Ontology analysis of the genes differentially
regulated between WT & Mta1-KO with $2.0 fold change.
(DOC)
Figure 10. The genes differentially regulated (p-value,0.05 and fold change $±2.0) between the P53 knock out and the P53 knock
out with Mta1 over expressed MEFs (Mta1 regulated genes independent of P53) were subjected to the network analysis and the
most significant network found is associated with cancer and genetic disorders. Most of the genes in the network were found to be down
regulated in P53-KO/Mta1 when compared with P53-KO. All the upregulated genes are shown in red and the down regulated genes are shown in
green color.
doi:10.1371/journal.pone.0017135.g010
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regulated genes in the absence of P53 with $2.0 fold change.
(DOC)
Table S10 Primer sequences for the candidate genes of Mus
Musculus and Homo sapiens that were used in the RT-qPCR assays
are shown.
(DOC)
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